Adenosine A 2A receptor antagonists do not disrupt rodent prepulse inhibition: An improved side effect profile in the treatment of parkinson's disease

Parkinson's Disease

Volumn , Issue , 2012, Pages

  Bleickardt, Carina J ^a   Lashomb, Abigail L ^a   Merkel, Carrie E ^a   Hodgson, Robert A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

[7 [2 [4 (2,4 DIFLUOROPHENYL)] 1 PIPERAZINYL]ETHYL] 2 (2 FURANYL) 7H PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDIN 5 AMINE; ADENOSINE A2A RECEPTOR ANTAGONIST; APOMORPHINE; DOPAMINE RECEPTOR STIMULATING AGENT; ISTRADEFYLLINE; LEVODOPA; PERGOLIDE; PRAMIPEXOLE; PYRIMIDINE DERIVATIVE; ROPINIROLE; SCH 412348; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATALEPSY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDICATION; HUMAN; MALE; MOUSE; NONHUMAN; PARKINSON DISEASE; PREPULSE INHIBITION; PRIORITY JOURNAL; RAT; RODENT;

EID: 84855561896     PISSN: None     EISSN: 20420080     Source Type: Journal    
DOI: 10.1155/2012/591094     Document Type: Article

References (31)

1. Gallagher D. A., Lees A. J., Schrag A., What are the most important nonmotor symptoms in patients with Parkinson's disease and are we missing them? Movement Disorders 2010 25 15 2493 2500
2. Goldman J. G., Vaughan C. L., Goetz C. G., An update expert opinion on management and research strategies in Parkinson's disease psychosis Expert Opinion on Pharmacotherapy 2011 12 13 2009 2024
3. Fénelon G., Mahieux F., Huon R., Ziégler M., Hallucinations in parkinson's disease. Prevalence, phenomenology and risk factors Brain 2000 123 4 733 745 (Pubitemid 30162723)
4. Barnes J., David A. S., Visual hallucinations in Parkinson's disease: a review and phenomenological survey Journal of Neurology Neurosurgery and Psychiatry 2001 70 6 727 733 (Pubitemid 32554201)
5. Ecker D., Unrath A., Kassubek J., Sabolek M., Dopamine agonists and their risk to induce psychotic episodes in Parkinson's disease: a case-control study BioMed Central Neurology 2009 9 23 1 6
6. Goetz C. G., Tanner C. M., Klawans H. L., Pharmacology of hallucinations induced by long-term drug therapy The American Journal of Psychiatry 1982 139 4 494 497 (Pubitemid 12141048)
7. Papapetropoulos S., Mash D. C., Psychotic symptoms in Parkinson's disease: from description to etiology Journal of Neurology 2005 252 7 753 764 (Pubitemid 40984849)
8. Zahodne L. B., Fernandez H. H., Pathophysiology and treatment of psychosis in Parkinson's disease: a review Drugs and Aging 2008 25 8 665 682
9. Zahodne L. B., Fernandez H. H., Parkinson's psychosis Current Treatment Options in Neurology 2010 12 3 200 211
10. Swerdlow N. R., Taaid N., Oostwegel J. L., Randolph E., Geyer M. A., Towards a cross-species pharmacology of sensorimotor gating: effects of amantadine, bromocriptine, pergolide and ropinirole on prepulse inhibition of acoustic startle in rats Behavioural Pharmacology 1998 9 5-6 389 396
11. Weber M., Chang W. L., Breier M., Ko D., Swerdlow N. R., Heritable strain differences in sensitivity to the startle gating-disruptive effects of D2 but not D3 receptor stimulation Behavioural Pharmacology 2008 19 8 786 795
12. Swerdlow N. R., Lelham S. A., Sutherland Owens A. N., Chang W. L., Sassen S. D., Talledo J. A., Pramipexole effects on startle gating in rats and normal men Psychopharmacology 2009 205 4 689 698
13. Augood S. J., Emson P. C., Adenosine A 2A receptor mRNA is expressed by enkephalin cells but not by somatostatin cells in rat striatum: a co-expression study Molecular Brain Research 1994 22 14 204 210
14. Hettinger B. D., Lee A., Linden J., Rosin D. L., Ultrastructural localization of adenosine A 2A receptors suggests multiple cellular sites for modulation of GABAergic neurons in rat striatum Journal of Comparative Neurology 2001 431 3 331 346 (Pubitemid 32115298)
15. Hauser R. A., Cantillon M., Pourcher E., Micheli F., Mok V., Onofrj M., Huyck S., Wolski K., Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial The Lancet Neurology 2011 10 3 221 229
16. Shiozaki S., Ichikawa S., Nakamura J., Kitamura S., Yamada K., Kuwana Y., Actions of adenosine A 2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP Psychopharmacology 1999 147 1 90 95 (Pubitemid 30010028)
17. Hodgson R. A., Bertorelli R., Varty G. B., Lachowicz J. E., Forlani A., Fredduzzi S., Cohen-Williams M. E., Higgins G. A., Impagnatiello F., Nicolussi E., Parra L. E., Foster C., Zhai Y., Neustadt B. R., Stamford A. W., Parker E. M., Reggiani A., Hunter J. C., Characterization of the potent and highly selective A 2A receptor antagonists preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1- piperazinyl]ethyl]-2-(2-furanyl)-7hpyrazolo[ 4,3-e][1,2,4]triazolo[1,5-c] pyrimidin-5-amine in rodent models of movement disorders and depression Journal of Pharmacology and Experimental Therapeutics 2009 330 1 294 303
18. Schwarzschild M. A., Agnati L., Fuxe K., Chen J. F., Morelli M., Targeting adenosine A 2A receptors in Parkinson's disease Trends in Neurosciences 2006 29 11 647 654 (Pubitemid 44602262)
19. Morelli M., Di Paolo T., Wardas J., Calon F., Xiao D., Schwarzschild M. A., Role of adenosine A 2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications Progress in Neurobiology 2007 83 5 293 309 (Pubitemid 350102747)
20. Chang W. L., Swerdlow N. R., Breier M. R., Thangaraj N., Weber M., Parametric approaches towards understanding the effects of the preferential D 3 receptor agonist pramipexole on prepulse inhibition in rats Pharmacology Biochemistry and Behavior 2010 95 4 473 478
21. Etminan M., Gill S., Samii A., Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis Drug Safety 2003 26 6 439 444 (Pubitemid 36560715)
22. Stoner S. C., Dahmen M. M., Makos M., Lea J. W., Carver L. J., Rasu R. S., An exploratory retrospective evaluation of ropinirole-associated psychotic symptoms in an outpatient population treated for restless legs syndrome or Parkinson's disease The Annals of Pharmacotherapy 2009 43 9 1426 1432
23. Coldwell M. C., Boyfield I., Brown T., Hagan J. J., Middlemiss D. N., Comparison of the functional potencies of ropinirole and other dopamine receptor agonists at human D 2(long), D 3 and D 4.4 receptors expressed in Chinese hamster ovary cells British Journal of Pharmacology 1999 127 7 1696 1702 (Pubitemid 29369006)
24. Fox S. H., Visanji N. P., Johnston T. H., Gomez-Ramirez J., Voon V., Brotchie J. M., Dopamine receptor agonists and levodopa and inducing psychosis-like behavior in the MPTP primate model of Parkinson disease Archives of Neurology 2006 63 9 1343 1344 (Pubitemid 44379848)
25. Ferré S., Quiroz C., Woods A. S., Cunha R., Popoli P., Ciruela F., Lluis C., Franco R., Azdad K., Schiffmann S. N., An update on adenosine A 2A -dopamine D 2 receptor interactions: implications for the function of G protein-coupled receptors Current Pharmaceutical Design 2008 14 15 1468 1474 (Pubitemid 351997812)
26. Stevenson C. W., Gratton A., Role of basolateral amygdala dopamine in modulating prepulse inhibition and latent inhibition in the rat Psychopharmacology 2004 176 2 139 145 (Pubitemid 39517943)
27. Fuxe K., Ferré S., Canals M., Torvinen M., Terasmaa A., Marcellino D., Goldberg S. R., Staines W., Jacobsen K. X., Lluis C., Woods A. S., Agnati L. F., Franco R., Adenosine A 2A and dopamine D2 heteromeric receptor complexes and their function Journal of Molecular Neuroscience 2005 26 2-3 209 219 (Pubitemid 41389413)
28. Koch M., Hauber W., Regulation of sensorimotor gating by interactions of dopamine and adenosine in the rat Behavioural Pharmacology 1998 9 1 23 29 (Pubitemid 28098664)
29. Fénelon G., Psychosis in Parkinson's disease: phenomenology, frequency, risk factors, and current understanding of pathophysiologic mechanisms CNS Spectrums 2008 13 3, supplement 4 18 25 (Pubitemid 351532445)
30. Good C. H., Hoffman A. F., Hoffer B. J., Chefer V. I., Shippenberg T. S., Backman C. M., Larsson N.-G., Olson L., Gellhaar S., Galter D., Lupica C. R., Impaired nigrostriatal function precedes behavioral deficits in a genetic mitochondrial model of Parkinson's disease The Faseb Journal 2011 25 4 1333 1344
31. Marcellino D., Lindqvist E., Schneider M., Mller C. E., Fuxe K., Olson L., Galter D., Chronic A 2A antagonist treatment alleviates parkinsonian locomotor deficiency in MitoPark mice Neurobiology of Disease 2010 40 2 460 466